Search results
Results from the WOW.Com Content Network
[21] [134] [20] [135] [19] [136] [137] [138] [22] These proteins are involved in the metabolism and elimination of xenobiotics, and as a result, their induction by spironolactone may contribute to drug interactions of spironolactone. [21] [134] [20] Examples of such interactions include oral digoxin and estradiol. [136] [79]
Spironolactone, sold under the brand ... also have numerous other interactions, ... menstrual irregularities and breast side effects of spironolactone and to its drug ...
Compared to the second-generation NSAAs, enzalutamide and apalutamide, bicalutamide has inferior potency and efficacy but similar tolerability and safety and a lower propensity for drug interactions. Relative to steroidal antiandrogens like cyproterone acetate and spironolactone , bicalutamide has better selectivity in its action, superior ...
Potassium-sparing diuretics or antikaliuretics [1] refer to drugs that cause diuresis without causing potassium loss in the urine. [2] They are typically used as an adjunct in management of hypertension , cirrhosis , and congestive heart failure . [ 3 ]
However, spironolactone is metabolized to three active metabolites, which give it prolonged activity (13.8 – 16. 5 hours). Spironolactone has a long half-life and is excreted 47-51% through kidneys. Patients with chronic kidney disease therefore require close monitoring when taking the drug. Spironolactone is also eliminated through feces (35-41%
[191] [62] However, spironolactone was introduced in 1959., [192] [193] although its antiandrogen effects were not recognized or taken advantage of until later and were originally an unintended off-target action of the drug. [194] In addition to spironolactone, chlormadinone acetate and megestrol acetate are steroidal antiandrogens that are ...
Canrenone is an active metabolite of spironolactone, canrenoic acid, and potassium canrenoate, and is considered to be partially responsible for their effects. [9] It has been found to have approximately 10 to 25% of the potassium-sparing diuretic effect of spironolactone, [ 16 ] whereas another metabolite, 7α-thiomethylspironolactone (7α-TMS ...
These drugs inhibit the first and rate-limiting step of the renin–angiotensin–aldosterone system (RAAS), namely the conversion of angiotensinogen to angiotensin I. This leads to a totality in absence of angiotensin II based on the rationale that renin only acts to inhibit this step unlike Angiotensin Converting Enzyme which is also involved ...